Prostate Cancer Update

Featuring an interview with Dr Rana R McKay, including the following topics:Prostate Cancer Working Group (PCWG4) revised terminology (0:00)Cardiovascular effects associated with GnRH agonists versus antagonists; mechanism of action (2:17)Combination therapy using relugolix; factors affecting persistence and adherence to GnRH agents (12:06)Takeaways from the Phase III EMBARK study (19:36)Use of CAR (chimeric antigen receptor) T-cell therapy and T-cell engagers (27:20)Potential role of circulating tumor DNA minimal residual disease testing; use of olaparib/radium-223 (29:24)CME information and select publications

Featuring perspectives from Dr Alexandra Drakaki, Ms Krisztina Emodi, Dr Terence Friedlander and Ms Margarita Huober, moderated by Dr Friedlander, including the following topics:Introduction: Basic Biology of Nonmetastatic Urothelial Bladder Cancer (UBC) (0:00)Systemic Therapy for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer (MIBC) (13:35)Evolving Approach to Systemic Therapy for Cisplatin-Ineligible Patients with MIBC (37:13)Immune Checkpoint Inhibitors in Non-Muscle-Invasive Bladder Cancer (58:55)Novel Intravesical Therapies for Nonmetastatic UBC (1:10:20)NCPD information and select publications

Featuring perspectives from Dr Ashish M Kamat and Prof Thomas Powles, including the following topics:Introduction: Life After Radical Cystectomy (0:00)Muscle-Invasive Bladder Cancer — Prof Powles (9:15)Non-Muscle-Invasive Bladder Cancer — Dr Kamat (37:49)CME information and select publications

Featuring perspectives from Dr Neeraj Agarwal and Dr Alan H Bryce, including the following topics:Introduction (0:00)Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer — Dr Bryce (2:41)Other Available and Emerging Therapeutic Approaches — Dr Agarwal (35:16)CME information and select publications

Featuring perspectives from Dr Terence Friedlander and Dr Daniel P Petrylak, including the following topics:Introduction (0:00)Role of Immunotherapeutic Strategies in the Management of Nonmetastatic Urothelial Bladder Cancer (UBC); Emerging Utility of Circulating Tumor DNA Evaluation — Dr Friedlander (3:53)Other Novel Agents and Strategies for Nonmetastatic and Metastatic UBC — Dr Petrylak (26:41)CME information and select publications

Featuring perspectives from Dr Neeraj Agarwal, Dr Elisabeth I Heath, Dr Daniel P Petrylak, Dr Fred Saad and Dr Neal D Shore, moderated by Dr Heath, including the following topics:Introduction (0:00)Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Shore (2:12)Current Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Petrylak (27:54)Current and Future Role of PARP Inhibitors for Metastatic Prostate Cancer (mPC) — Dr Agarwal (50:49)Emerging Role of AKT Inhibition for Patients with mHSPC — Dr Heath (1:13:12)Current and Future Use of Radiopharmaceuticals for mPC — Dr Saad (1:37:26)CME information and select publications

Dr Thomas Hutson from the Sarah Cannon Research Institute in Abilene, Texas, Dr Eric A Singer from The Ohio State University Comprehensive Cancer Center in Columbus and Dr Ulka Vaishampayan from the University of Michigan Health Rogel Cancer Center in Ann Arbor discuss recent data surrounding the management of localized renal cell carcinoma and share their perspectives on the clinical application.CME information and select publications

Professor Thomas Powles from Barts Cancer Institute in London, United Kingdom, discusses recent developments with circulating tumor DNA assays in the management of urothelial bladder cancer.CME information and select publications

Professor Thomas Powles from Barts Cancer Institute in London, United Kingdom, discusses recent developments with circulating tumor DNA assays in the management of urothelial bladder cancer. CME information and select publications here.

Dr Wassim Abida from Memorial Sloan Kettering Cancer Center in New York, New York, discusses the role of PARP inhibitors in the management of hormone-sensitive and castration-resistant metastatic prostate cancer.CME information and select publications here.

Dr Andrew J Armstrong from the Duke Cancer Institute in Durham, North Carolina, and Dr Scott T Tagawa from Weill Cornell Medicine Meyer Cancer Center in New York, New York, discuss the selection and sequencing of therapy for patients with prostate cancer and summarize major advances in the treatment landscape over the past year.CME information and select publications here.

Dr Matthew Milowsky from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, comments on real patient cases of metastatic urothelial bladder cancer presented by Dr Jacqueline T Brown from the Emory University School of Medicine in Atlanta, Georgia, and Dr Nazli Dizman from The University of Texas MD Anderson Cancer Center in Houston.CME information and select publications here.

Prof Karim Fizazi from the Centre Oscar Lambret in Lille, France, Dr Daniel George from the Duke Cancer Institute in Durham, North Carolina, and moderator Dr Elisabeth I Heath from Mayo Clinic in Rochester, Minnesota, discuss the future role of AKT inhibition in prostate cancer.CME information and select publications here.

Dr Matthew Milowsky from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, comments on real patient cases of metastatic urothelial bladder cancer presented by Dr Jacqueline T Brown from the Emory University School of Medicine in Atlanta, Georgia and Dr Nazli Dizman from The University of Texas MD Anderson Cancer Center in Houston. CME information and select publications here.

Dr Matthew D Galsky from The Tisch Cancer Institute in New York, New York, Dr Shilpa Gupta from Cleveland Clinic’s Taussig Cancer Institute in Ohio, Prof Andrea Necchi from IRCCS San Raffaele Hospital in Milan, Italy, and moderator Dr Terence Friedlander from the University of California, San Francisco discuss recent data surrounding the management of non-muscle-invasive and muscle-invasive bladder cancer, alongside their perspectives on clinical application and disease management.CME information and select publications here.

Dr Terence Friedlander discusses the selection and sequencing of therapy for patients with bladder cancer and reviews clinical findings recently presented at the 2025 ESMO Congress.CME information and select publications here.

Dr Fern Anari from the Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Dr Catherine Fahey from the Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, present real patient cases on metastatic bladder cancer, with additional commentary from Dr Matthew Galsky from The Tisch Cancer Institute in New York, New York.CME information and select publications here.

Dr McKay discusses the selection of and efficacy data with androgen pathway-targeting agents for patients with prostate cancer and reviews recently presented clinical findings from the ESMO Congress 2025.CME information and select publications here.

Dr Terence Friedlander discusses the selection and sequencing of therapy for patients with bladder cancer and reviews clinical findings recently presented at the 2025 ESMO Congress.CME information and select publications here.

Dr Rana R McKay discusses the selection and sequencing of therapy for patients with prostate cancer in a review of recently presented clinical findings from ESMO Congress 2025.CME information and select publications here.

Dr Catherine Fahey from the Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Fern Anari from the Fox Chase Cancer Center in Philadelphia, Pennsylvania, present real patient cases on metastatic bladder cancer, with additional commentary from Dr Matthew Galsky from The Tisch Cancer Institute in New York, New York.CME information and select publications here.

Dr Terence Friedlander from the UCSF Helen Diller Family Comprehensive Cancer Center and Dr Rana R McKay from the UC San Diego Moores Cancer Center summarize the treatment landscape for prostate and urothelial bladder cancer and discuss the implications of clinical findings recently presented at the ESMO Congress 2025.CME information and select publications here.

Dr Emmanuel S Antonarakis and Dr Matthew R Smith share their perspectives on the evolving therapeutic landscape for patients with prostate cancer. CME information and select publications here.

Dr Jonathan Strosberg from Moffitt Cancer Center in Tampa, Florida, discusses recent updates on available and novel treatment strategies for extrapulmonary neuroendocrine carcinoma. CME information and select publications here.

Ms Kathleen D Burns from City of Hope Comprehensive Cancer Center in Duarte, California, discusses nursing considerations in the care of patients with prostate cancer. NCPD information and select publications here.

Prof Laurence Albiges and Dr Tian Zhang summarize major findings presented at the 2025 ASCO Annual Meeting and review relevant ongoing clinical trials for patients with renal cell carcinoma. CME information and select publications here.

Dr Rahul Aggarwal and Dr William K Oh and nurse practitioners Ms Monica Averia and Ms Kathleen D Burns discuss the current treatment landscape for prostate cancer and protocols to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.

Dr Matthew D Galsky from The Tisch Cancer Institute in New York, New York, Prof Andrea Necchi from the IRCCS San Raffaele Hospital in Milan, Italy, and Prof Thomas Powles from the Barts Cancer Institute in London provide their perspectives on clinical scenarios and datasets informing the care of patients with urothelial bladder cancer. CME information and select publications here.

Dr Neeraj Agarwal from the University of Utah Huntsman Cancer Institute in Salt Lake City, Dr Andrew J Armstrong from Duke Cancer Institute in Durham, North Carolina, Dr Himisha Beltran from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Fred Saad from the University of Montreal Hospital Center in Québec, Canada, and Dr Rana R McKay from the UC San Diego Moores Cancer Center discuss recent updates on available and novel treatment strategies for prostate cancer. CME information and select publications here.

Dr Leonard G Gomella from the Sidney Kimmel Cancer Center in Philadelphia, Pennsylvania, Dr Evan Y Yu from the Fred Hutchinson Cancer Center in Seattle, Washington, and Dr Daniel George from Duke Cancer Institute in Durham, North Carolina, discuss important clinical datasets and patient cases relevant to AKT inhibition in the care of patients with prostate cancer. CME information and select publications here.

Clinical investigators discuss available data guiding the management of urothelial bladder cancer.  CME information and select publications here.

Dr Emmanuel S Antonarakis from the University of Minnesota in Minneapolis and Professor Karim Fizazi from the Institut Gustave Roussy in Villejuif, France, provide their perspectives on relevant new clinical data in prostate cancer and discuss their application to the care of patients. CME information and select publications here.

Clinical investigators discuss available data guiding the management of prostate cancers. CME information and select publications here.

Dr William Oh from the Yale Cancer Center in New Haven, Connecticut, discusses recent updates on available and novel treatment strategies for genitourinary cancers. CME information and select publications here.

Dr Thomas Hutson from UMC Cancer Center in Lubbock, Texas, Dr Rana McKay from UC San Diego Moores Cancer Center in California, Dr Tian Zhang from UT Southwestern Medical Center in Dallas, and moderator Dr Sumanta Kumar Pal from City of Hope Comprehensive Cancer Center in Duarte, California, discuss published data and updates from the 2025 ASCO Genitourinary Cancers Symposium meeting on management strategies for clear cell and non-clear cell renal cell carcinoma.  CME information and select publications here.

Drs Terence Friedlander, Matthew D Galsky, Neeraj Agarwal, Andrew J Armstrong and Elisabeth I Heath discuss recent updates on available and novel treatment strategies for bladder cancer and prostate cancer. CME information and select publications here.

Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with prostate cancer.

Dr Michiel van der Heijden from the Netherlands Cancer Institute in Amsterdam discusses the management of metastatic urothelial bladder cancer.

Dr Matthew R Smith from the Massachusetts General Hospital Cancer Center in Boston summarizes recent developments presented at ASCO 2024 for prostate cancer.

Dr Rana R McKay from Moores Cancer Center in La Jolla, California, and Prof Thomas Powles from Barts Cancer Institute in London, United Kingdom, discuss recent updates on available and novel treatment strategies for renal cell carcinoma.

Dr Petros Grivas from the Fred Hutchinson Cancer Center in Seattle, Washington, discusses the current management of advanced urothelial bladder cancer.

Dr Matthew Galsky from The Tisch Cancer Institute in New York and Dr Ashish Kamat from The University of Texas MD Anderson Cancer Center in Houston summarize recent clinical advances in the management of urothelial bladder cancer, including data from the 2024 AUA annual meeting.

Dr Matthew D Galsky from Icahn School of Medicine at Mount Sinai in New York, New York, summarizes treatment options for patients with HER2-altered genitourinary cancers and reviews recent emerging clinical trial data in the field.

Dr Emmanuel Antonarakis from the University of Minnesota in Minneapolis reviews research findings presented at the 2024 Genitourinary Cancers Symposium and provides his perspectives on current and novel treatment approaches for prostate cancer.

Dr Shilpa Gupta from the Taussig Cancer Institute in Cleveland, Ohio, and Prof Thomas Powles from the Barts Cancer Institute in London, United Kingdom, discuss clinical decision-making with numerous treatment strategies for urothelial bladder cancer.

Dr Manish Patel from the Florida Cancer Specialists & Research Institute in Sarasota, Florida, discusses drug development, early-phase clinical trials and the emerging field of B7-H3-targeted antibody-drug conjugates for solid tumors.

Dr Andrew J Armstrong from the Duke Cancer Institute Center in Durham, North Carolina and Dr Maha Hussain from Robert H Lurie Comprehensive Cancer Center in Chicago summarize recent data sets from 2023 on hormonal therapies and other emerging treatment approaches for patients with prostate cancer.

Drs Petros Grivas, Vadim S Koshkin, Kriti Mittal, Mamta Parikh and Scott T Tagawa discuss available and emerging research, patient cases from participating junior clinical investigators and the perspectives of senior clinical investigator faculty on data informing their decision-making for patients with metastatic urothelial bladder cancer.

Dr Neal Shore from the Carolina Urologic Research Center in Myrtle Beach, South Carolina, and Dr Mary-Ellen Taplin from the Dana-Farber Cancer Institute in Boston, Massachusetts, discuss the current and future management of high-risk, hormone-sensitive nonmetastatic prostate cancer.

Dr Rana McKay from UC San Diego Moores Cancer Center in La Jolla, California discusses key presentations on genitourinary cancers from the 2023 ASCO Annual Meeting.